- Home
- BCDA vs IMCC Comparison
BCDA vs IMCC Comparison
Compare BCDA & IMCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- IMCC
- Stock Information
- Founded
- BCDA N/A
- IMCC 1980
- Country
- BCDA United States
- IMCC Israel
- Employees
- BCDA N/A
- IMCC N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- IMCC Medicinal Chemicals and Botanical Products
- Sector
- BCDA Health Care
- IMCC Health Care
- Exchange
- BCDA Nasdaq
- IMCC Nasdaq
- Market Cap
- BCDA 9.4M
- IMCC 7.5M
- IPO Year
- BCDA N/A
- IMCC N/A
- Fundamental
- Price
- BCDA $1.92
- IMCC $1.42
- Analyst Decision
- BCDA Strong Buy
- IMCC
- Analyst Count
- BCDA 1
- IMCC 0
- Target Price
- BCDA $25.00
- IMCC N/A
- AVG Volume (30 Days)
- BCDA 93.6K
- IMCC 9.2K
- Earning Date
- BCDA 05-13-2025
- IMCC 05-07-2025
- Dividend Yield
- BCDA N/A
- IMCC N/A
- EPS Growth
- BCDA N/A
- IMCC N/A
- EPS
- BCDA N/A
- IMCC N/A
- Revenue
- BCDA $58,000.00
- IMCC $37,551,778.00
- Revenue This Year
- BCDA N/A
- IMCC $47.12
- Revenue Next Year
- BCDA N/A
- IMCC $12.83
- P/E Ratio
- BCDA N/A
- IMCC N/A
- Revenue Growth
- BCDA N/A
- IMCC 10.71
- 52 Week Low
- BCDA $1.63
- IMCC $1.29
- 52 Week High
- BCDA $6.15
- IMCC $7.86
- Technical
- Relative Strength Index (RSI)
- BCDA 38.14
- IMCC 53.33
- Support Level
- BCDA $1.73
- IMCC $1.29
- Resistance Level
- BCDA $1.93
- IMCC $1.56
- Average True Range (ATR)
- BCDA 0.13
- IMCC 0.13
- MACD
- BCDA -0.01
- IMCC 0.04
- Stochastic Oscillator
- BCDA 30.95
- IMCC 100.00
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.